$0.06
(9.16%)
Add to watchlist
Create an alert
Stocks and Shares ISAIO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Company Information
About this company
Key people
Mai-Britt Zocca
President, Chief Executive Officer, Founder, Director
Amy B. Sullivan
Chief Financial Officer, Principal Accounting Officer
Brian Burkavage
Senior Vice President, Chief Accounting Officer
Devin Whittemore Smith
General Counsel, Company Secretary
Qasim Ahmad
Chief Medical Officer
Faical Miyara
Chief Business Officer
Peter Hirth
Chairman of the Board
Helen Louise Collins
Director
Christian E. Elling
Independent Director
Kathleen Sereda Glaub
Independent Director
Heidi Hunter
Independent Director
Click to see more
Key facts
- Shares in issue71.95m
- EPICIOBT
- ISINUS4497781090
- LocationDenmark
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$46.00m
- Employees80
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.